CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps

By João L. Carapinha

February 24, 2025

How can decision analytic models improve cardiovascular disease prevention in Sub-Saharan Africa? A recent article on the application of decision analytic modelling to cardiovascular disease prevention in Sub-Saharan Africa explored the use of decision analytic models (DAMs) for evaluating interventions aimed at cardiovascular disease (CVD) prevention in Sub-Saharan Africa (SSA). It highlights that CVDs represent a significant burden in SSA, with an upward trend observed over the last three decades.

The review encompasses 27 studies from eight SSA countries, concentrating on model-based economic evaluations of CVD prevention models. Most studies focused on primary CVD prevention, with pharmacological interventions, particularly antihypertensives and statins, being most common. Markov models were frequently utilized, and the Framingham risk equations were applied to estimate 10-year CVD risk.

Notes from the Study

Most studies centered on primary CVD prevention, with pharmacological interventions being the predominant focus. Markov models and microsimulation models were the most utilized, with Markov models appearing in 13 studies and microsimulation models in seven. Only seven studies integrated equity dimensions, primarily through subgroup analysis, focusing on gender, socioeconomic, and regional inequalities.

Significant data gaps emerged, especially concerning intervention effectiveness and CVD risk equations, highlighting a lack of local data for generating 10-year CVD risk assessments. The mean quality score of the papers was 68.9%, although inconsistencies and data limitations were apparent, with only three studies undertaking model validation.

Health Economic Implications

The findings emphasize the necessity for enhanced health economic evaluations that factor in equity dimensions to guide policy decisions on CVD prevention in SSA. Longitudinal studies are essential for refining CVD risk prediction and local health outcome valuation studies. The review indicated that policymakers must prioritize cost-effective and equitable interventions to strive for universal health coverage (UHC). Strengthening primary healthcare systems is vital for scaling up effective CVD prevention models.

Future Studies

Future studies should aim to address primordial prevention and lifestyle interventions, which are currently undervalued. There is also an urgent need for improved model validation, calibration, and stakeholder engagement in the modeling process.

The review highlighted the importance of adhering to best practices in developing DAMs, such as utilizing local data, ensuring model validation, and maintaining transparency in the modeling process. The absence of local data for generating 10-year CVD risk equations and utility values for QALYs reveals significant research gaps. Incorporating equity considerations in economic evaluations is crucial, particularly through newer methods like extended and distributional cost-effectiveness analyses. There is a call for increased emphasis on longitudinal studies and local health valuation studies to enhance the accuracy and relevance of CVD prevention models in SSA.

Reference url

Recent Posts

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

Sword Health mental health
         

How Does Mind’s AI-Driven Mental Healthcare Transform Care?

🤔 Are we ready to embrace AI in mental health care?

Sword Health has just secured €34.6 million to launch **Mind**, an innovative AI-powered mental health solution, blending licensed clinicians with continuous monitoring through wearables. This strategic expansion aims to address the pressing global mental health crisis while promoting personalized and proactive care models. 🌍🧠

Dive into how Sword Health is revolutionizing healthcare and bridging the gap between technology and clinical expertise.

#SyenzaNews #HealthTech #AIinHealthcare #DigitalTransformation

transparency in industry partnerships
   

Transparency in Industry Partnerships: Building Trust

🔍 How does transparency in industry partnerships impact patient care?

In the evolving landscape of healthcare, EFPIA’s mandatory disclosure requirements for financial interactions underscore the vital role of transparency in fostering trust and collaboration. By detailing financial transfers to healthcare professionals and organizations, the European Disclosure Gateway facilitates informed decision-making and strengthens relationships between stakeholders.

Have a look at the article to explore how these initiatives not only enhance public confidence but also drive innovation in treatments!

#SyenzaNews #HealthcareInnovation #HealthEconomics #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.